Loading...
Publication
Genomic characterisation of a novel KPC-98-producing clinical Klebsiella pneumoniae strain conferring resistance to ceftazidime/avibactam
| Name: | Description: | Size: | Format: | |
|---|---|---|---|---|
| 612.91 KB | Adobe PDF |
Advisor(s)
Abstract(s)
Ceftazidime/avibactam (CZA) is a novel drug that inactivates Ambler class A, including Klebsiella pneumoniae carbapenemases (KPC), class C and class D β-lactamases, but is not active against metallo-β-lactamases (class B). Despite its limited use worldwide, emerging cases of CZA-resistant isolates producing variants
of the blaKPC gene have been reported. In this study, we report a novel KPC-98 variant conferring CZA resistance identified in a highly virulent and multidrug-resistant clinical isolate of K. pneumoniae, belonging to the high-risk international clone sequence type 13 (ST13).
Description
© 2023 Elsevier Ltd and International Society of Antimicrobial Chemotherapy. All rights reserved.
Keywords
Pedagogical Context
Citation
Int J Antimicrob Agents. 2023 Dec;62(6):107013
Publisher
Elsevier